China NMPA Drug Inspection - Kangpu Pharmaceutical Co., Ltd. - Acyclovir tablets

The Ningxia Food and Drug Administration issued its "Drug Quality Sampling Inspection Information Announcement (No. 04, 2017)" on June 9, 2017. This announcement details the findings from regional drug sampling inspections conducted as part of the 2017 work plan. The inspections covered a total of 96 batches, encompassing 40 different drug varieties. This included 66 batches of 21 chemical drugs and 30 batches of 19 traditional Chinese medicine decoction pieces, sourced from various manufacturers and dispensaries within the region. The regulatory framework for these assessments primarily involved adherence to the Chinese Pharmacopoeia (2010 and 2015 editions), as well as specific Ministry of Health Drug Standards and National Drug Standards. A key finding of this announcement is that all inspected batches passed their quality checks. The document explicitly states that "All inspection results meet the requirements." Consequently, no violations or issues were identified, and no corrective actions were required for the companies or products featured in this particular announcement, signifying full compliance with applicable drug quality standards.